Rimonabant: From RIO to Ban

Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside...

Descripción completa

Detalles Bibliográficos
Autores principales: Sam, Amir H., Salem, Victoria, Ghatei, Mohammad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136184/
https://www.ncbi.nlm.nih.gov/pubmed/21773005
http://dx.doi.org/10.1155/2011/432607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136184/
https://www.ncbi.nlm.nih.gov/pubmed/21773005
http://dx.doi.org/10.1155/2011/432607

Ejemplares similares